Our work
Dr. Schneider’s lab focuses on HIV antibody distribution. He has helped develop a platform to track intravenous injected fluorophore conjugated IgG in plasma, tissue, and weck-cel fluid. This methodology has led to a grant to study how the timing of antibody injection affects distal site accumulation of virus following challenge. Through a better understanding of how antibodies get to and fortify mucosal surfaces from incoming pathogens, this research has the potential to elucidate novel HIV prevention strategies with the ultimate goal of blocking initial HIV transmission. This work will help inform future passive immunization studies, such as the AMP (Antibody Mediated Prevention) trial which is currently underway and administering anti-HIV antibodies to at-risk individuals around the world. As the SARS-CoV-2 pandemic emerged, I have adapted my work with HIV antibodies to better understand the neutralizing antibody response in COVID-19 patients.
Impact of work
Technology
Funding
- NIH K01OD024882: "The role of steady state broadly neutralizing antibody tissue levels in preventing distal site SHIV replication"
- NIH R21MH125339: “Imaging the CNS SIV reservoir in a cART cessation model”
- Walder Foundation Grant, “Characterizing the neutralizing antibody response in SARS-CoV-2 infected individuals”
- Walder Foundation Grant, “Characterizing the long-term durability and composition of COVID-19 vaccine induced antibodies”
- Walder Foundation Grant, “B3: Boosters, Breakthroughs, and Biorepositories”
Our team
- Alia Alia (PhD Candidate)
- Michelle Ash (PhD Candidate)
- Gabrielle Kooi (PhD Candidate)
- Anjelica Reyes (Lab Tech 3)
- Samantha Welninski (Lab Tech 2)
Contact us
We welcome inquiries about our research, collaborations and funding. Please contact Jeffrey R. Schneider, PhD.